Department of Pharmacology and Institute of New Drug Development, Chonbuk National University, Jeonju 54689, Republic of Korea.
Graduate School, DGIST, Daegu 42988, Republic of Korea.
Hum Reprod. 2018 Mar 1;33(3):378-389. doi: 10.1093/humrep/dex381.
Is the Transmembrane BAX Inhibitor Motif-6 (TMBIM6) involved in the molecular mechanism by which cisplatin causes reproductive toxicity?
TMBIM6 protects against cisplatin-induced testicular toxicity through up-regulation of heme oxygenase-1 (HO-1),-which maintains the levels of steroidogenic enzymes by decreaseing oxidative stress in the endoplasmic reticulum (ER).
Testosterone production is highly suppressed as a main complication of cisplatin (cis-diamminedichloroplatinum) anticancer therapy.
STUDY DESIGN, SIZE, DURATION: Groups of seven wild type or Tmbim6 KO C57BL/6J mice were given a single i.p., injection of cisplatin (30 mg/kg body wt) and testis and serum were collected 3 days later. Tmbim6-lentivirus-mediated testicular expression-rescued KO mice were analyzed to confirm function was restored. Tmbim6-over expressing TM3 mouse Leydig cells were exposed to cisplatin in vitro.
PARTICIPANTS/MATERIALS, SETTING, METHODS: After collection of the specimens serum testosterone level and testicular weight and structure were compared between the groups. Quantitative PCR, immunoblot, and assays for ROS, HO-1 activity and protein disulfide isomerase (PDI) carbonylation were performed.
Phospho protein kinase B (p-Akt), nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2), and its downstream gene product HO-1 and the levels of testosterone synthesis-associated enzymes, including steroidogenic acute regulatory protein (StAR), a rate limiting enzyme for testosterone production, were significantly expressed in the presence of Tmbim6 and maintained after cisplatin treament. Excessive post-translational oxidation of protein disulfide isomerase (PDI), altered folding capacitance and ROS accumulation, and ER stress were also decreased in the presence of Tmbim6. Higher levels of ER stress and protein hypercarbonylation were consistently observed in KO testis, compared with WT testis. In the Tmbim6 KO mice, lentivirus-mediated testicular expression of Tmbim6 rescued the above phenotypes. Furthermore, the protective role of Tmbim6 against testicular toxicity was consistently shown in Tmbim6-overexpressing TM3 Leydig cells (testosterone producing cells). We conclude that TMBIM6 protects against cisplatin-induced testicular toxicity by inducing HO-1 and enhancing ER folding capacitance.
N/A.
LIMITATIONS, REASONS FOR CAUTION: This study was performed using a short, 3-day cisplatin treatment condition. Therefore, the results need to be cautiously interpreted with regard to cisplatin-associated chronic toxicity. Moreover, to determine the clinical relevance of the role of TMBIM6, further studies in testicular cancer are needed.
Cisplatin-associated ER stress and redox imbalance might be implicated as toxicity mechanisms associated with anticancer therapy.
STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Research Foundation of Korea (2015R1A2A1A13001849). The authors have no competing interests to disclose.
跨膜 BAX 抑制剂基序-6(TMBIM6)是否参与顺铂引起生殖毒性的分子机制?
TMBIM6 通过上调血红素加氧酶-1(HO-1)来保护睾丸免受顺铂诱导的毒性,HO-1 通过减少内质网(ER)中的氧化应激来维持类固醇生成酶的水平。
顺铂(顺二氨二氯铂)抗癌治疗的主要并发症是睾丸酮产生受到高度抑制。
研究设计、规模、持续时间:7 组野生型或 Tmbim6 KO C57BL/6J 小鼠接受单次腹腔注射顺铂(30mg/kg 体重),3 天后收集睾丸和血清。分析 Tmbim6-慢病毒介导的睾丸表达挽救 KO 小鼠以确认功能恢复。Tmbim6 过表达 TM3 小鼠睾丸间质细胞在体外暴露于顺铂。
参与者/材料、设置、方法:收集标本后,比较各组血清睾丸酮水平和睾丸重量和结构。进行定量 PCR、免疫印迹和 ROS、HO-1 活性和蛋白二硫键异构酶(PDI)羰基化测定。
磷酸蛋白激酶 B(p-Akt)、红细胞系 2(NFE2)相关因子 2(Nrf2)及其下游基因产物 HO-1 和睾丸酮合成相关酶的水平,包括类固醇急性调节蛋白(StAR),均在 Tmbim6 存在下显著表达,并且在顺铂处理后仍保持表达。在 Tmbim6 存在下,蛋白二硫键异构酶(PDI)的过度翻译后氧化、改变的折叠容量和 ROS 积累以及内质网应激也减少了。与 WT 睾丸相比,KO 睾丸中始终观察到更高水平的 ER 应激和蛋白过度羰基化。在 Tmbim6 KO 小鼠中,慢病毒介导的睾丸 Tmbim6 表达挽救了上述表型。此外,Tmbim6 在 Tmbim6 过表达 TM3 睾丸间质细胞(产生睾丸酮的细胞)中对睾丸毒性的保护作用也得到了一致的证明。
我们得出结论,TMBIM6 通过诱导 HO-1 和增强 ER 折叠容量来防止顺铂诱导的睾丸毒性。
无。
局限性、谨慎的原因:这项研究使用了 3 天的顺铂短期治疗条件。因此,需要谨慎解释与顺铂相关的慢性毒性的结果。此外,为了确定 TMBIM6 的作用的临床相关性,需要进一步在睾丸癌中进行研究。
顺铂相关的内质网应激和氧化还原失衡可能与抗癌治疗相关的毒性机制有关。
研究资金/利益冲突:本研究得到韩国国家研究基金会(2015R1A2A1A13001849)的支持。作者没有利益冲突需要披露。